Industry

ETTLINGEN, Germany–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today has launched PhenoRisk PACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson. The PhenoRisk PACS™ RuO test is promising … [Read more…]

Strategic alliance significantly expands ongoing multi-year collaboration by granting Turnstone broader access and enhanced benefits at Moffitt IND approval received for a Moffitt-sponsored Phase 1 study of TIDAL-01 in melanoma NEW YORK & TAMPA, Fla.–(BUSINESS WIRE)–#TIL–Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Zolpidem (CAS 82626-48-0) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Zolpidem. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Tioclomarol (CAS 22619-35-8) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Tioclomarol. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Norfloxacin (CAS 70458-96-7) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Norfloxacin. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

Dutch hospital drives AI initiatives on a modern analytics and data lakehouse to support data-driven decision making and improve patient care AMSTERDAM–(BUSINESS WIRE)–Hewlett Packard Enterprise (NYSE: HPE) today announced that Catharina Hospital, the largest hospital in the Netherlands’ Eindhoven region, providing care for over 150,000 patients, has selected the HPE Ezmeral software portfolio to build … [Read more…]

LAUSANNE, Switzerland–(BUSINESS WIRE)–Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, today announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million … [Read more…]

INGELHEIM, Germany & HAMBURG, Germany & MARCY-L’ÉTOILE, France–(BUSINESS WIRE)–Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials … [Read more…]

BRANFORD, Conn. & NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (the “TASE”). Based upon … [Read more…]

– Mosunetuzumab could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin’s lymphoma – – Application is based on results from the pivotal Phase I/II study showing mosunetuzumab induced high and durable complete response rates in people with follicular lymphoma who received two or … [Read more…]